Health
Moderna and Merck skin cancer vaccine cuts relapse risk
Pharmaceutical companies Moderna and Merck have announced positive Phase 3 clinical trial results for their personalized mRNA skin cancer vaccine intismeran.
Bringing you stories that vibe with your fashion